Zhitong Finance APP learned that more studies have proved that the existing new crown vaccine is effective against the Omi Keron variant, and some anti-epidemic stocks bucked the market and rose on Monday. US stocks closed on Monday, BioNTech SE (NASDAQ:)(BNTX.US) rose 7.97%, Pfizer Pharmaceuticals (NYSE:)(PEF.US) rose 4.59%, Moderna Inc (NASDAQ:)(MRNA.US) rose 5.81%, AstraZeneca (NASDAQ:) (AZN.US) rose 1.04%.
It is reported that last weekend, an Israeli study of 40 participants found that the level of antibodies that can resist the Omi Keron variant increased significantly in people who were vaccinated with the Pfizer/BioNTech new crown vaccine booster. Pfizer and BioNTech also issued a statement last week saying that their three-shot course of the new crown vaccine can neutralize the Omi Keron variant in laboratory tests.
At the same time, a study by the University of Oxford found that the Omi Keron variant would weaken the protection provided by the first two doses of Pfizer and AstraZeneca vaccines, but this does not indicate that the Omi Keron variant caused severe illness or death. The possibility is increased; in addition, the study also shows that the strengthening needle can increase the protective effect of the Omi Keron variant to a certain extent.
Fusion MediaOr anything withFusion MediaThe person concerned does not accept any liability for loss or damage caused by relying on the data, quotations, charts and buy/sell signals contained in this website. Please fully understand the risks and costs associated with financial market transactions. This is one of the most risky forms of investment. The English version of this agreement is the main version. If there is a discrepancy between the English version and the Chinese version, the English version shall prevail.